ADC Therapeutics SA
Combination therapy with an anti-axl antibody-drug conjugate
Last updated:
Abstract:
The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer. In particular, the present disclosure relates to combination therapies comprising treatment with an Antibody Drug Conjugate (ADC) and a secondary agent.
Status:
Grant
Type:
Utility
Filling date:
21 Nov 2018
Issue date:
28 Jan 2020